How Tesamorelin Affects ALT and Liver Fat

Tesamorelin reduces ALT and AST through liver fat reduction:

1. Hepatic steatosis is the primary driver of mildly elevated ALT/AST in metabolically syndromic populations. Reducing liver fat fraction directly lowers transaminase release.
2. Visceral fat reduction reduces portal FFA flux: Tesamorelin mobilises visceral fat preferentially. As VAT decreases, free fatty acid delivery to the liver drops, hepatic de novo lipogenesis decreases, and intrahepatic triglyceride stores are mobilised.
3. GH-mediated hepatic lipid oxidation: GH directly upregulates hepatic fatty acid oxidation. The pulsatile GH amplification from tesamorelin promotes intrahepatic fat clearance without the continuous GH exposure cost.
4. Anti-inflammatory hepatic transcriptome shift: Fourman et al. (2020, PMID 32701508) showed in paired liver biopsies that tesamorelin shifted hepatic gene expression toward oxidative phosphorylation and away from inflammation and fibrosis pathways. This explains the ALT/AST improvement beyond simple lipid clearance.

Standard dose (1.4-2 mg/day, subcutaneous):

• Hepatic fat fraction (MRI-PDFF): -4.1% absolute, -37% relative at 12 months (Stanley 2019 Lancet HIV)
• Liver fat normalisation (<5% HFF): 35% of patients achieve this at 12 months vs 4% placebo (p=0.0069)
• ALT and AST: trend downward as steatosis improves, magnitude proportional to baseline elevation
• INSTI subgroup: 31% relative HFF reduction (p=0.006) confirms benefit even on confounding co-medications

Comparison to GLP-1s on NAFLD:

• Tesamorelin: 35% normalisation rate at 12 months
• Semaglutide: comparable or slightly higher normalisation in NAFLD trials, but with concurrent caloric restriction
• Tesamorelin works without caloric restriction, making it useful as an adjunct to TRT and resistance training

Timeline: ALT/AST improvement begins by 12 weeks, with meaningful HFF reduction documented at 6-12 months.

Baseline: ALT, AST, GGT, bilirubin. If history suggests NAFLD (obesity, metabolic syndrome, oral AAS history), add liver ultrasound or FibroScan. MRI-PDFF is the gold standard but rarely accessible outside research settings.

During use:

• ALT, AST at week 12 (early signal)
• ALT, AST at week 26 (efficacy)
• ALT, AST every 12 weeks thereafter if continuing
• Imaging (FibroScan or MRI-PDFF) at 12 months if baseline NAFLD diagnosis

Interpretation:

• Falling ALT/AST: hepatic steatosis improving, continue
• Stable ALT/AST in already-normal baseline: protective effect, continue
• Rising ALT/AST: investigate other causes (concurrent oral AAS, alcohol, supplements). Tesamorelin itself does not cause hepatotoxicity in the Phase 3 dataset.

Maximising hepatic benefit:

• Discontinue or minimise oral 17-alpha-alkylated compounds (anavar, winstrol, dianabol, anadrol) during the tesamorelin block. Concurrent oral AAS hepatotoxicity will mask or override tesamorelin's hepatic benefit.
• Add 600 mg/day NAC and 250-500 mg/day TUDCA if running through an oral AAS block. See our TUDCA/NAC article for details.
• Combine with caloric protein-adequate intake. Tesamorelin does not require caloric deficit, but maintaining lean mass through adequate protein (1.6-2.2 g/kg/day) optimises body composition response.

If ALT/AST rise on tesamorelin:

• Tesamorelin is not hepatotoxic in the Phase 3 dataset (n=806, 52 weeks). A rising trend almost always reflects a concurrent factor.
• Check for concurrent oral AAS, alcohol intake, supplement use (especially high-dose niacin, biotin, or methylated B-complex)
• Recheck after 4-week washout of confounding factors
• If transaminases remain elevated, investigate viral hepatitis, autoimmune hepatitis, or hereditary haemochromatosis as alternative aetiologies